Twist Bioscience [TWST] vs Danaher [DHR] Detailed Stock Comparison
Twist Bioscience
NASDAQ
Loading...
Danaher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Twist Bioscience wins in 5 metrics, Danaher wins in 13 metrics, with 0 ties. Danaher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Twist Bioscience | Danaher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -7.35 | 44.88 | Twist Bioscience |
| Price-to-Book Ratio | 3.53 | 2.89 | Danaher |
| Debt-to-Equity Ratio | 19.48 | 35.45 | Twist Bioscience |
| PEG Ratio | 0.06 | -1.20 | Danaher |
| EV/EBITDA | -12.84 | 22.16 | Twist Bioscience |
| Profit Margin (TTM) | -23.52% | 14.21% | Danaher |
| Operating Margin (TTM) | -31.36% | 20.12% | Danaher |
| EBITDA Margin (TTM) | N/A | 20.12% | N/A |
| Return on Equity | -17.58% | 6.68% | Danaher |
| Return on Assets (TTM) | -13.88% | 4.01% | Danaher |
| Free Cash Flow (TTM) | $-69.17M | $5.30B | Danaher |
| 1-Year Return | -39.37% | -24.34% | Danaher |
| Price-to-Sales Ratio (TTM) | 4.67 | 6.29 | Twist Bioscience |
| Enterprise Value | $1.53B | $166.64B | Danaher |
| EV/Revenue Ratio | 4.23 | 6.94 | Twist Bioscience |
| Gross Profit Margin (TTM) | 53.40% | 59.35% | Danaher |
| Revenue per Share (TTM) | $6 | $33 | Danaher |
| Earnings per Share (Diluted) | $-1.44 | $4.70 | Danaher |
| Beta (Stock Volatility) | 2.37 | 0.76 | Danaher |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Twist Bioscience vs Danaher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Twist Bioscience | 8.05% | -8.22% | -23.87% | -7.02% | -35.92% | -41.58% |
| Danaher | 3.85% | -3.01% | 8.42% | 9.15% | -3.01% | -11.27% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Twist Bioscience | -39.37% | -38.58% | -61.61% | 89.07% | 89.07% | 89.07% |
| Danaher | -24.34% | -17.95% | 11.85% | 244.48% | 725.84% | 1,045.51% |
Performance & Financial Health Analysis: Twist Bioscience vs Danaher
| Metric | TWST | DHR |
|---|---|---|
| Market Information | ||
| Market Cap | $1.69B | $151.04B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,427,440 | 3,241,650 |
| 90 Day Avg. Volume | 1,577,357 | 4,189,007 |
| Last Close | $28.60 | $211.76 |
| 52 Week Range | $24.28 - $55.33 | $171.00 - $279.90 |
| % from 52W High | -48.31% | -24.34% |
| All-Time High | $214.07 (Jan 18, 2021) | $296.06 (Sep 06, 2021) |
| % from All-Time High | -86.64% | -28.47% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.18% | 0.03% |
| Quarterly Earnings Growth | 0.18% | -0.39% |
| Financial Health | ||
| Profit Margin (TTM) | -0.24% | 0.14% |
| Operating Margin (TTM) | -0.31% | 0.20% |
| Return on Equity (TTM) | -0.18% | 0.07% |
| Debt to Equity (MRQ) | 19.48 | 35.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $7.95 | $73.10 |
| Cash per Share (MRQ) | $4.16 | $4.13 |
| Operating Cash Flow (TTM) | $-51,134,000 | $6.17B |
| Levered Free Cash Flow (TTM) | $-24,547,124 | $3.88B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Twist Bioscience vs Danaher
| Metric | TWST | DHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -7.35 | 44.88 |
| Forward P/E | -11.53 | 25.17 |
| PEG Ratio | 0.06 | -1.20 |
| Price to Sales (TTM) | 4.67 | 6.29 |
| Price to Book (MRQ) | 3.53 | 2.89 |
| Market Capitalization | ||
| Market Capitalization | $1.69B | $151.04B |
| Enterprise Value | $1.53B | $166.64B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.23 | 6.94 |
| Enterprise to EBITDA | -12.84 | 22.16 |
| Risk & Other Metrics | ||
| Beta | 2.37 | 0.76 |
| Book Value per Share (MRQ) | $7.95 | $73.10 |
Financial Statements Comparison: Twist Bioscience vs Danaher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TWST | DHR |
|---|---|---|
| Revenue/Sales | $92.79M | $5.74B |
| Cost of Goods Sold | $46.77M | $2.23B |
| Gross Profit | $46.03M | $3.51B |
| Research & Development | $23.92M | $379.00M |
| Operating Income (EBIT) | $-41.56M | $1.27B |
| EBITDA | $-32.61M | $1.87B |
| Pre-Tax Income | $-39.15M | $1.13B |
| Income Tax | $175,000 | $175.00M |
| Net Income (Profit) | $-39.33M | $954.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TWST | DHR |
|---|---|---|
| Cash & Equivalents | $210.44M | $1.99B |
| Total Current Assets | $338.44M | $9.53B |
| Total Current Liabilities | $74.98M | $6.65B |
| Long-Term Debt | $65.08M | $15.98B |
| Total Shareholders Equity | $440.11M | $50.86B |
| Retained Earnings | $-1.31B | $44.91B |
| Property, Plant & Equipment | $155.13M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TWST | DHR |
|---|---|---|
| Operating Cash Flow | $-17.45M | $1.47B |
| Capital Expenditures | $-4.14M | $-239.00M |
| Free Cash Flow | $-17.13M | $1.05B |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | $-5,000 | $-1.08B |
Short Interest & Institutional Ownership Analysis
| Metric | TWST | DHR |
|---|---|---|
| Shares Short | 10.44M | 8.45M |
| Short Ratio | 11.50 | 1.93 |
| Short % of Float | 0.20% | 0.01% |
| Average Daily Volume (10 Day) | 2,427,440 | 3,241,650 |
| Average Daily Volume (90 Day) | 1,577,357 | 4,189,007 |
| Shares Outstanding | 58.88M | 719.10M |
| Float Shares | 59.26M | 637.13M |
| % Held by Insiders | 0.02% | 0.11% |
| % Held by Institutions | 1.17% | 0.83% |
Dividend Analysis & Yield Comparison: Twist Bioscience vs Danaher
| Metric | TWST | DHR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |